Alzheimer's Disease

A new study estimates that 6.3 million Canadians will be diagnosed and living with dementia in the next 30 years (Photo: Alzheimer Society)

Canada could see tripling of people living with dementia in next 30 years: Landmark study

The Alzheimer Society of Canada released a study that predicts triple the number of diagnoses

 

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

U.S. approves much-debated Alzheimer’s drug aducanumab panned by experts

Drug from Biogen deemed “reasonably likely” to benefit Alzheimer’s patients